APA (7th ed.) Citation

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., . . . Copland, M. (2017). A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: Data from the British DESTINY study. Elsevier.

Chicago Style (17th ed.) Citation

Clark, Richard E., et al. A Phase 2 Trial of Decreasing Tyrosine Kinase Inhibitor Dose in Chronic Myeloid Leukaemia Patients with Stable Major Molecular Response: Data from the British DESTINY Study. Elsevier, 2017.

MLA (9th ed.) Citation

Clark, Richard E., et al. A Phase 2 Trial of Decreasing Tyrosine Kinase Inhibitor Dose in Chronic Myeloid Leukaemia Patients with Stable Major Molecular Response: Data from the British DESTINY Study. Elsevier, 2017.